|
Clinical characteristics of patients |
|||||||
| Patient |
Age in years |
Gender |
Disease duration in years |
Anti-SSA/Anti-SSB/RF |
Extraglandular manifestations |
Prednisolone (mg/day) |
Adverse events |
|
|
|||||||
| 1a |
59 |
Female |
13 |
+/+/+ |
Arthralgia |
- |
Vertigo, perspiration |
| 2 |
46 |
Female |
12 |
+/+/+ |
LP, RS |
- |
GI discomfort, common cold |
| 3a |
50 |
Female |
15 |
+/+/+ |
Arthralgia, RS, LP |
- |
GI discomfort |
| 4 |
67 |
Female |
17 |
+/+/+ |
Arthralgia, RS |
2.5 |
None |
| 5 |
60 |
Female |
4 |
+/+/+ |
Arthralgia, LP, VA |
- |
GI discomfortb |
| 6a |
61 |
Female |
5 |
+/+/+ |
Arthralgia, LP |
- |
Pneumonia |
| 7 |
53 |
Female |
13 |
+/-/+ |
LP, PNP |
2.5 |
GI discomfort, herpes labialis |
| 8 |
40 |
Female |
2 |
+/-/- |
Arthralgia, LP |
- |
None |
| 9 |
35 |
Female |
12 |
+/-/+ |
LP, RS |
5 |
None |
| 10 |
44 |
Female |
9 |
+/+/+ |
Arthralgia, RS |
- |
Palpitation, perspirationb |
| 11 |
36 |
Female |
2 |
+/+/- |
Arthralgia |
- |
Common cold |
|
aPatients 1, 3, and 6 did not complete the study; bdose was reduced to 720 mg/day after week 12. GI, gastrointestinal; LP, leukopenia; PNP, polyneuropathy; RF, rheumatoid factor; RS, Raynaud syndrome; VA, vasculitis. | |||||||
Willeke et al. Arthritis Research & Therapy 2007 9:R115 doi:10.1186/ar2322 |
|||||||